Building Scientific Narratives and Publications for Early-Phase Gene Therapies
Introduction
Our client had a wide array of innovative gene therapy candidates being explored in the cardiology and neurology spaces, featuring a distinct mechanism of action and utilizing cutting-edge vector technology. Two of these candidates were in early Phase I clinical development to treat rare cardiac disorders, with robust pre-clinical data demonstrating promising results in animal models.
The Problem
The client’s primary need was to strategically craft and develop clear scientific narratives for their two major assets. This was not just about publishing a wealth of pre-clinical data or presenting at major gene therapy and cardiology conferences, but about laying the foundation for these narratives and increasing awareness for trial recruitment.
Our Solution
- Developed fit-for-purpose scientific narratives and a lexicon to ensure cohesive communication with healthcare providers, investors, and patients, aligning with clinical and corporate strategies
- Collaborated with external authors and internal medical affairs, clinical development, and research teams
- Supported the development of two manuscripts: one on in vivo studies of gene therapy in animals and another comparing novel vector technology with standard gene therapy
Value Delivered
- Crafted scientific narratives and a lexicon that were cross-functionally validated, scientifically robust, high-impact, and aspirational for cohesive communication with key audiences
- Created more than a dozen posters and oral presentations for key congresses supporting data communication and trial recruitment
- Boosted scientific visibility through supported manuscripts
